Insider Selling: Natera (NASDAQ:NTRA) CFO Sells $614,329.24 in Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Burkes Brophy sold 2,419 shares of the company’s stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total transaction of $614,329.24. Following the completion of the transaction, the chief financial officer owned 54,295 shares of the company’s stock, valued at $13,788,758.20. This trade represents a 4.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Michael Burkes Brophy also recently made the following trade(s):

• On Wednesday, July 29th, Michael Burkes Brophy sold 1,863 shares of Natera stock. The shares were sold at an average price of $249.38, for a total transaction of $464,594.94.
• On Monday, July 27th, Michael Burkes Brophy sold 782 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $203,703.18.
• On Monday, May 4th, Michael Burkes Brophy sold 482 shares of Natera stock. The shares were sold at an average price of $210.49, for a total transaction of $101,456.18.
• On Friday, May 1st, Michael Burkes Brophy sold 313 shares of Natera stock. The stock was sold at an average price of $206.16, for a total transaction of $64,528.08.

Natera Price Performance

NTRA stock opened at $267.76 on Friday. Natera, Inc. has a 1 year low of $131.81 and a 1 year high of $288.04. The firm has a 50-day moving average of $246.77 and a 200 day moving average of $222.22. The company has a market cap of $38.35 billion, a P/E ratio of -164.27 and a beta of 1.51.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. BTIG Research set a $275.00 target price on Natera and gave the stock a “buy” rating in a research report on Wednesday, June 24th. Royal Bank Of Canada started coverage on Natera in a research report on Thursday, June 11th. They set an “outperform” rating and a $275.00 price target on the stock. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Piper Sandler reiterated an “overweight” rating and issued a $249.00 price objective on shares of Natera in a report on Tuesday, May 12th. Finally, UBS Group set a $260.00 price objective on Natera in a report on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $267.83.

Institutional Investors Weigh In On Natera

Several hedge funds have recently added to or reduced their stakes in the stock. Integrated Wealth Concepts LLC grew its stake in shares of Natera by 6.6% in the first quarter. Integrated Wealth Concepts LLC now owns 1,560 shares of the medical research company’s stock worth $221,000 after acquiring an additional 96 shares during the last quarter. NewEdge Advisors LLC increased its holdings in shares of Natera by 68.3% during the first quarter. NewEdge Advisors LLC now owns 4,552 shares of the medical research company’s stock valued at $644,000 after acquiring an additional 1,847 shares in the last quarter. Focus Partners Wealth raised its position in shares of Natera by 8.6% in the 1st quarter. Focus Partners Wealth now owns 5,993 shares of the medical research company’s stock worth $847,000 after purchasing an additional 474 shares during the last quarter. Sivia Capital Partners LLC purchased a new position in shares of Natera in the 2nd quarter worth about $298,000. Finally, WINTON GROUP Ltd bought a new position in Natera in the 2nd quarter worth about $558,000. 99.90% of the stock is owned by institutional investors.

About Natera

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.